Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients: A 3-year randomized, placebo-controlled study

@article{citeulike:2690277, abstract = {OBJECTIVE--To investigate the efficacy of orlistat on the maintenance of weight loss over 3 years following a major weight loss induced by very-low-energy diet (VLED) in obese patients with metabolic risk factors such as dyslipidemia, impaired fasting glucose, and diet-treated type 2 diabetes. RESEARCH DESIGN AND METHODS--Initially, weight loss was induced by an 8-week VLED (600-800 kcal/day) in 383 patients with a mean BMI of 37.5 kg/m2 (range 30.0-45.2). Those who lost [\&ge;]5\% of their body weight (309 of 383 patients) were then randomized to receive lifestyle counseling for 3 years together with either orlistat 120 mg t.i.d. or matching placebo capsules. Primary end points were the maintenance of [\&ge;]5\% weight loss after 3 years. Additionally, differences in the development of type 2 diabetes between orlistat and placebo were analyzed. RESULTS--The VLED induced a mean weight loss of 14.4 {+/-} 2..0 kg among the subsequently randomized patients. The mean weight gain after 3 years was lower with orlistat than with placebo (4.6 {+/-} 8.6 vs. 7.0 {+/-} 7.1 kg; P < 0.02). The number of participants who achieved [\&ge;]5\% weight loss also favored orlistat (67 vs. 56\%; P = 0.037). Waist circumference was significantly more reduced in the orlistat group (P < 0.05), but no other differences in the risk factors were observed between the two groups. The incidences of new cases of type 2 diabetes were significantly reduced in the orlistat group (8 cases out of 153 subjects) versus placebo (17 cases out of 156 subjects) (P = 0.041). CONCLUSIONS--The addition of orlistat to lifestyle intervention was associated with maintenance of an extra 2.4 kg weight loss after VLED for up to 3 years in obese subjects. The combination of orlistat and lifestyle intervention was associated with a reduced occurrence of type 2 diabetes. 10.2337/dc06-0210}, author = {Richelsen, Bjorn and Tonstad, Serena and Rossner, Stephan and Toubro, Soren and Niskanen, Leo and Madsbad, Steen and Mustajoki, Pertti and Rissanen, Aila }, citeulike-article-id = {2690277}, doi = {10.2337/dc06-0210}, journal = {Diabetes Care}, keywords = {diet, drugs, obese}, month = {January}, number = {1}, pages = {27--32}, posted-at = {2008-04-19 09:41:53}, priority = {2}, title = {Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients: A 3-year randomized, placebo-controlled study}, url = {http://dx.doi.org/10.2337/dc06-0210}, volume = {30}, year = {2007} }

TY - JOUR ID - citeulike:2690277 L3 - citeulike-article-id:2690277 TI - Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients: A 3-year randomized, placebo-controlled study JF - Diabetes Care VL - 30 IS - 1 SP - 27 EP - 32 N2 - OBJECTIVE--To investigate the efficacy of orlistat on the maintenance of weight loss over 3 years following a major weight loss induced by very-low-energy diet (VLED) in obese patients with metabolic risk factors such as dyslipidemia, impaired fasting glucose, and diet-treated type 2 diabetes. RESEARCH DESIGN AND METHODS--Initially, weight loss was induced by an 8-week VLED (600-800 kcal/day) in 383 patients with a mean BMI of 37.5 kg/m2 (range 30.0-45.2). Those who lost [&ge;]5% of their body weight (309 of 383 patients) were then randomized to receive lifestyle counseling for 3 years together with either orlistat 120 mg t.i.d. or matching placebo capsules. Primary end points were the maintenance of [&ge;]5% weight loss after 3 years. Additionally, differences in the development of type 2 diabetes between orlistat and placebo were analyzed. RESULTS--The VLED induced a mean weight loss of 14.4 {+/-} 2..0 kg among the subsequently randomized patients. The mean weight gain after 3 years was lower with orlistat than with placebo (4.6 {+/-} 8.6 vs. 7.0 {+/-} 7.1 kg; P < 0.02). The number of participants who achieved [&ge;]5% weight loss also favored orlistat (67 vs. 56%; P = 0.037). Waist circumference was significantly more reduced in the orlistat group (P < 0.05), but no other differences in the risk factors were observed between the two groups. The incidences of new cases of type 2 diabetes were significantly reduced in the orlistat group (8 cases out of 153 subjects) versus placebo (17 cases out of 156 subjects) (P = 0.041). CONCLUSIONS--The addition of orlistat to lifestyle intervention was associated with maintenance of an extra 2.4 kg weight loss after VLED for up to 3 years in obese subjects. The combination of orlistat and lifestyle intervention was associated with a reduced occurrence of type 2 diabetes. 10.2337/dc06-0210 KW - diet KW - drugs KW - obese AU - Richelsen, Bjorn AU - Tonstad, Serena AU - Rossner, Stephan AU - Toubro, Soren AU - Niskanen, Leo AU - Madsbad, Steen AU - Mustajoki, Pertti AU - Rissanen, Aila PY - 2007/01/01/ UR - http://dx.doi.org/10.2337/dc06-0210 ER -